Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China

Details werden geladen...

https://www.biospace.com/business/serapha-takes-reverse-merger-route-to-nasdaq-with-230m-and-gene-editor-from-china

Teilen bei Facebook
Teilen bei Twitter
Teilen bei Pinterest
Per Mail empfehlen

Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China - BioSpace

The combined business entity with Boundless Bio, which will carry Serapha Bio’s name and fold in Boundless Bio, will focus on the development of a gene editor for alpha-1 antitrypsin deficiency.

Registrieren

Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China - BioSpace